Alnylam Pharmaceuticals (ALNY) Change in Accured Expenses (2009 - 2026)

Alnylam Pharmaceuticals has reported Change in Accured Expenses for 18 years, with the latest figure at -$176.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 11.6% year-over-year to -$176.0 million; the trailing twelve-month figure through Mar 2026 stood at $56.8 million (up 191.89% YoY), and the FY2025 full-year result was $75.1 million, down 17.59% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$176.0 million, down from -$174.9 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $223.5 million in Q3 2025, with the low at -$176.0 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $15.5 million across 5 years, with a median of $68.1 million in 2022.
• The largest YoY upside for Change in Accured Expenses was 167.37% in 2025 against a maximum downside of 3142.24% in 2025.
• Alnylam Pharmaceuticals' Change in Accured Expenses stood at $102.6 million in 2022, then tumbled by 137.68% to -$38.7 million in 2023, then slumped by 60.62% to -$62.1 million in 2024, then plunged by 181.54% to -$174.9 million in 2025, then declined by 0.67% to -$176.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$176.0 million (Q1 2026), -$174.9 million (Q4 2025), and $223.5 million (Q3 2025), per Business Quant data.